乙基4-乙氧基-3-羟基苯甲酸酯 | 382150-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙基4-乙氧基-3-羟基苯甲酸酯
• 英文名称: 4-ethoxy-3-hydroxy-benzoic acid ethyl ester
• 英文别名: 4-ethoxy-3-hydroxybenzoic acid ethyl ester；ethyl 4-ethoxy-3-hydroxybenzoate；4-Aethoxy-3-hydroxy-benzoesaeure-aethylester
• CAS: 382150-30-3
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: DZSNTBDVMPRWQC-UHFFFAOYSA-N

物化性质

• 熔点：
  77-78 °C
• 沸点：
  351.2±22.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙基4-乙氧基-3-羟基苯甲酸酯 在 palladium on activated charcoal 、 氢气 、 硝酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 乙二醇二甲醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 7-ethoxyquinazoline-4,6-diol
  参考文献：
  名称：

  [EN] BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS
  [FR] BIS-ARYL ÉTHERS CONTENANT DE LA N-ACYL AZÉTIDINE EN TANT QU'INHIBITEURS DE L'EGFR/HER2

  摘要：

  该发明提供了化合物及其药物组合物，用于抑制EGFR和erbB2的活性，以及使用这些化合物来治疗与突变EGFR和erbB2活性相关的癌症的方法。

  公开号：

  WO2021231400A1
• 作为产物：
  描述：

  (3E,5EZ)-3-(ethoxycarbonyl)-6-ethoxy-3,5-hexadienoic acid 在 氯甲酸乙酯 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 0.5h， 以90%的产率得到乙基4-乙氧基-3-羟基苯甲酸酯
  参考文献：
  名称：

  通过苯环化反应从3-烷氧基羰基-3,5-二烯酸的区域特异性合成杂取代的酚。

  摘要：

  DOI：

  10.1021/jo010552f

文献信息

• New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa
  申请人：——

  公开号：US20020198195A1

  公开（公告）日：2002-12-26

  The present invention relates to compounds comprising the following formula: R 0 —Q—X—Q′—W—U—V—G—M  (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

  本发明涉及包含以下公式的化合物： R 0 —Q—X—Q′—W—U—V—G—M  (I) 这些化合物作为药物活性化合物是有用的。它们展现出抗血栓作用，并适用于例如治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。这些化合物是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆性抑制剂，通常可用于治疗、预防或治愈存在因子Xa和/或因子VIIa不期望活性的情况，或旨在抑制因子Xa和/或因子VIIa的情况。本发明还涉及制备这些化合物的方法、它们的使用方法（例如，作为药品中的活性成分）以及包含它们的药物制剂。
• [EN] ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS FUSIONNÉS D'ACIDE CYCLOPENTANE-CARBOXYLIQUE À SUBSTITUTION ACYLAMINO, ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009135590A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及具有式(I)的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有权利要求中指出的含义，它们是有价值的药物活性化合物。具体而言，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体可被溶血磷脂酸（LPA）激活，也被称为LPA1受体，并且可用于治疗例如动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备式(I)化合物的方法、它们的使用以及包含它们的药物组合物。
• Inhibitors of factor Xa and factor VIIa
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1217000A1

  公开（公告）日：2002-06-26

  The present invention relates to compounds of the formula I,         R0-Q-X-Q'-W-U-V-G-M     (I) in which Q; X; Q', U, V, G and M have the meanings indicated in the claims; R0 is aryl or heteroaryl; and W is selected from aryl, heteroaryl, carbocyclic and heterocyclic groups. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa(FXa) and/or factor VIIa(FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及具有以下式I的化合物，其中Q；X；Q'；U，V，G和M具有索引中指示的含义；R0为芳基或杂芳基；W从芳基、杂芳基、碳环和杂环基中选择。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa不良活性的情况或预期抑制因子Xa和/或因子VIIa以治疗或预防的情况。本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla
  申请人：Nazare Marc

  公开号：US20050165058A1

  公开（公告）日：2005-07-28

  The present invention relates to compounds comprising the following formula: R 0 -Q-X-Q′-W—U—V-G-M  (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

  本发明涉及以下式子的化合物：R0-Q-X-Q′-W—U—V-G-M（I）。这些化合物可用作药理活性化合物。它们表现出抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。这些化合物是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于治疗，预防或治愈存在因子Xa和/或因子VIIa的不良活性或需要抑制因子Xa和/或因子VIIa的情况。本发明还涉及制备这些化合物的方法，它们的使用方法（例如，作为药物的活性成分）以及包含它们的制药制剂。
• Oxybenzamide derivatives useful for inhibiting factor Xa or viia
  申请人：Nazaré Marc

  公开号：US06953857B2

  公开（公告）日：2005-10-11

  The present invention relates to compounds comprising the following formula: R 0 —Q—X—Q′—W—U—V—G—M  (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

  本发明涉及以下公式的化合物：R0-Q-X-Q′-W-U-V-G-M (I)。这些化合物可用作药理活性化合物。它们表现出抗血栓作用，适用于治疗和预防心血管疾病，例如血栓栓塞性疾病或再狭窄。这些化合物是血液凝血酶酶因子Xa（FXa）和/或酶因子VIIa（FVIIa）的可逆抑制剂，通常可用于治疗、预防或治愈存在酶因子Xa和/或酶因子VIIa不良活性或需要抑制酶因子Xa和/或酶因子VIIa的情况。本发明还涉及制备这些化合物的方法、它们的使用方法（例如作为药物的活性成分）以及包含它们的制药制剂。